Ontology highlight
ABSTRACT: Patient summary
The IMvigor130 trial showed that addition of atezolizumab to chemotherapy (CTx) did not improve survival over CTx alone in patients with bladder cancer. Overall, patients whose cancer did not progress during initial treatment tended to live longer than patients whose cancer did progress, but addition of atezolizumab to CTx did not help either group live longer in comparison to CTx alone. However, the results suggest that patients who received a certain CTx drug (cisplatin) or who had high levels of a marker called PD-L1 in their tumour may get the most improvement from addition of atezolizumab to CTx.The IMvigor130 trial is registered on ClinicalTrials.gov as NCT02807636.
SUBMITTER: Grande E
PROVIDER: S-EPMC10632822 | biostudies-literature | 2023 Dec
REPOSITORIES: biostudies-literature
Grande Enrique E Bamias Aristotelis A Galsky Matthew D MD Kikuchi Eiji E Davis Ian D ID Arranz José Ángel JÁ Rezazadeh Kalebasty Arash A Garcia Del Muro Xavier X Park Se Hoon SH De Giorgi Ugo U Alekseev Boris B Mencinger Marina M Izumi Kouji K Puente Javier J Li Jian-Ri JR Bernhard Sandrine S Nicholas Alan A Telliez Julie J De Santis Maria M
European urology open science 20231104
Standard-of-care first-line treatment for metastatic urothelial carcinoma (mUC) is platinum-based chemotherapy (CTx). Maintenance immunotherapy is a treatment option for patients without progressive disease (PD) after induction CTx. IMvigor130 was a randomised, phase 3 study evaluating atezolizumab plus platinum-based CTx (arm A), atezolizumab monotherapy (arm B), or placebo plus platinum-based CTx (arm C) as first-line treatment for mUC. The primary progression-free survival (PFS) analysis show ...[more]